0000950170-23-068373.txt : 20231205 0000950170-23-068373.hdr.sgml : 20231205 20231205185930 ACCESSION NUMBER: 0000950170-23-068373 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231201 FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lyon Joseph Douglas CENTRAL INDEX KEY: 0001817838 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 231468063 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2023-12-01 0001088856 CORCEPT THERAPEUTICS INC CORT 0001817838 Lyon Joseph Douglas C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 false true false false Chief Accounting Officer true Common Stock 2023-12-01 4 M false 2568 11.35 A 8422 D Common Stock 2023-12-01 4 S false 2568 26.00 D 5854 D Common Stock 2023-12-04 4 M false 2432 11.35 A 8286 D Common Stock 2023-12-04 4 S false 2432 26.00 D 5854 D Common Stock 2023-12-01 4 A false 460 25.97 A 6314 D Common Stock 2023-12-01 4 A false 460 0.00 A 6774 D Stock option (right to buy) 11.35 2023-12-01 4 M false 5000 0 D 2029-02-08 Common Stock 5000 44167 D Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on December 1, 2023. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. Fully exercisable. /s/ Joseph Douglas Lyon 2023-12-05